Health Care and the 2008 Election: Revolution, Reform or Return to Business-as-Usual?
This article was originally published in RPM Report
As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.
You may also be interested in...
The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.
As health reform enters a critical phase in Washington, the investment community is paying more attention than ever to the debate in Congress.
The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.